MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.
AACHEN, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a significant expansion of company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements.
Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors
PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...
DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.
BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...
The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.
Collaboration to support Safi IND data package for use of mRBCs in sickle cell disease chronic transfusions
CAMBRIDGE, Mass. and DETROIT, July 16, 2025 /PRNewswire/...
PALO ALTO, Calif., July 15, 2025 /PRNewswire/ -- Lucile Packard Children's Hospital Stanford, the cornerstone of Stanford Medicine Children's Health, is proud to announce...
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™
CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...